Use of NKG2D inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes

Details for Australian Patent Application No. 2010284428 (hide)

Owner The Penn State Research Foundation The Regents of the University of California

Inventors Xiong, Na; Xia, Mingcan; Raulet, David H.; Petersen, Jacob Sten; Bodvarsdottir, Thora Brynja

Agent Davies Collison Cave

Pub. Number AU-A-2010284428

PCT Pub. Number WO2011/022334

Priority 61/234,425 17.08.09 US; 61/304,113 12.02.10 US

Filing date 16 August 2010

Wipo publication date 24 February 2011

International Classifications

A61K 38/17 (2006.01) Medicinal preparations containing peptides - from animals

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 3/00 (2006.01) Drugs for disorders of the metabolism

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

Event Publications

16 February 2012 PCT application entered the National Phase

  PCT publication WO2011/022334 Priority application(s): WO2011/022334

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010284433-Combination therapy of cancer with anti-endoglin antibodies and anti-VEGF agents

2010284421-Fuel and engine oil composition and its use